Emergent BioSolutions faces questions from lawmakers in vaccine probe
Emergent BioSolutions executives testify on Capitol Hill
Replay Video
UP NEXT
The beleaguered biotech firm Emergent BioSolutions will face a congressional inquiry Wednesday, scrutinized for what investigators say are the "serious deficiencies" in their manufacturing that led to up to 15 million doses' worth of COVID-19 vaccine ingredients being compromised and disposed of because of cross-contamination.
Top Emergent executives Fuad El-Hibri, the company's founder and executive chairman, and Robert Kramer, its chief executive officer, will appear on Capitol Hill as part of a congressional investigation into their company's manufacturing issues, and whether the firm leveraged its ties with the Trump administration to improperly secure their pandemic contract worth millions of dollars.